Fedratinib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 294 publications
Development of a validated ultra-fast UPLC-MS/MS method for famciclovir quantification in human liver microsomes: NADPH-independent metabolic stability.
Journal: Analytical methods : advancing methods and applications
Published: October 26, 2026
Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.
Journal: Biomedicines
Published: September 18, 2026
A 1-Min UPLC-MS/MS Assay for the Wee1 Inhibitor Adavosertib in Human Liver Microsomes: Validation and Metabolic Stability Assessment.
Journal: Electrophoresis
Published: August 04, 2026
Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.
Journal: British journal of haematology
Published: June 15, 2026
Fedratinib treatment correlates with suppressed STAT3/AKT/calpain-1 signaling and inhibits hepatocellular carcinoma progression.
Journal: Translational gastroenterology and hepatology
Published: June 02, 2026
Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.
Journal: Frontiers in oncology
Published: May 10, 2026
Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.
Journal: Hematological oncology
Published: April 27, 2026
Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.
Journal: Leukemia & lymphoma
Published: April 15, 2026
Last Updated: 11/08/2026